MTHFD2L

Across TCGA pan-cancer cohorts, MTHFD2L mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MTHFD2L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MTHFD2L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MTHFD2L is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where MTHFD2L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTHFD2L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	−1.214	<.001	11	view →
HNSC	All	All	−0.752	.035	2	view →
LSCC	All	All	−0.253	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

MTHFD2L–CCRCC

Open the CCRCC breakdown →